Anti-Cardiolipin ELISA Kit

Anti-Cardiolipin (aCL) antibodies are autoantibodies directed against cardiolipin, a phospholipid component of mitochondrial membranes, often in complex with β2-glycoprotein I. These antibodies are central to the pathogenesis of antiphospholipid syndrome (APS), an autoimmune disorder characterized by arterial and venous thrombosis, recurrent pregnancy loss, and thrombocytopenia. Anti-cardiolipin antibodies can be of the IgG, IgM, or IgA isotypes, and their clinical significance depends on both titer and persistence over time. They promote a prothrombotic state by activating endothelial cells, platelets, and the coagulation cascade.

In the clinical setting, anti-cardiolipin testing is used to diagnose APS, particularly in patients with unexplained thrombosis, recurrent pregnancy complications, or in those with systemic lupus erythematosus (SLE), where APS frequently co-occurs. Positive results for medium- to high-titer IgG or IgM aCL antibodies, confirmed on repeat testing 12 weeks apart, are part of the revised Sapporo criteria for APS diagnosis. Clinically, anti-cardiolipin levels help assess thrombotic risk, guide anticoagulation therapy, and monitor disease activity in patients with APS or SLE.

In research, anti-cardiolipin antibodies serve as a biomarker for autoimmune thrombophilia and are studied to understand the mechanisms of immune-mediated clotting, vascular inflammation, and pregnancy loss. They are used in longitudinal studies to evaluate the development of APS in at-risk populations and in clinical trials investigating anticoagulant or immunomodulatory therapies. Anti-cardiolipin measurement also helps in exploring the interplay between autoimmunity, genetics, and environmental triggers in the development of thrombotic autoimmune disorders.

This product is manufactured in Germany by Medipan GmbH.